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Clinical, Angiographic, and Procedural Predictors of
Angiographic Restenosis After Sirolimus-Eluting Stent
Implantation in Complex Patients
An Evaluation From the Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospital (RESEARCH) Study
Pedro A. Lemos, MD; Angela Hoye, MB ChB, MRCP; Dick Goedhart; Chourmouzios A. Arampatzis, MD;
Francesco Saia, MD; Willem J. van der Giessen, MD, PhD; Eugene McFadden, MB ChB, FRCPI;
Georgios Sianos, MD; Pieter C. Smits, MD; Sjoerd H. Hofma, MD; Pim J. de Feyter, MD, PhD;
Ron T. van Domburg, PhD; Patrick W. Serruys, MD, PhD
Background—The factors associated with the occurrence of restenosis after sirolimus-eluting stent (SES) implantation in
complex cases are currently unknown.
Methods and Results—A cohort of consecutive complex patients treated with SES implantation was selected according to
the following criteria: (1) treatment of acute myocardial infarction, (2) treatment of in-stent restenosis, (3) 2.25-mm
diameter SES, (4) left main coronary stenting, (5) chronic total occlusion, (6) stented segment 36 mm, and (7)
bifurcation stenting. The present study population was composed of 238 patients (441 lesions) for whom 6-month
angiographic follow-up data were obtained (70% of eligible patients). Significant clinical, angiographic, and procedural
predictors of post-SES restenosis were evaluated. Binary in-segment restenosis was diagnosed in 7.9% of lesions (6.3%
in-stent, 0.9% at the proximal edge, 0.7% at the distal edge). The following characteristics were identified as
independent multivariate predictors: treatment of in-stent restenosis (OR 4.16, 95% CI 1.63 to 11.01; P0.01), ostial
location (OR 4.84, 95% CI 1.81 to 12.07; P0.01), diabetes (OR 2.63, 95% CI 1.14 to 6.31; P0.02), total stented
length (per 10-mm increase; OR 1.42, 95% CI 1.21 to 1.68; P0.01), reference diameter (per 1.0-mm increase; OR 0.46,
95% CI 0.24 to 0.87; P0.03), and left anterior descending artery (OR 0.30, 95% CI 0.10 to 0.69; P0.01).
Conclusions—Angiographic restenosis after SES implantation in complex patients is an infrequent event, occurring mainly
in association with lesion-based characteristics and diabetes mellitus. (Circulation. 2004;109:1366-1370.)
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In-stent restenosis is the major limitation hampering themedium-term efficacy of coronary stenting. Several reports
have evaluated the impact of baseline and procedural char-
acteristics on the risk of subsequent restenosis after bare
metal stent implantation, with a number of high-risk param-
eters, such as diabetes, lesion length, and vessel size, being
consistently identified in most studies.1–7 Unfortunately, these
characteristics are commonly found in the daily practice,
where treatment of complex patients frequently appears as a
challenging therapeutic dilemma.
Sirolimus-eluting stents (SESs) have been proven to strik-
ingly decrease neointimal growth, leading to a marked
reduction in restenosis rates.8–10 In the RAndomized study
with the sirolimus-eluting Bx VElocity balloon-expandable
stent in the treatment of patients with de novo native coronary
artery Lesions (RAVEL),8 no cases of binary angiographic
restenosis were seen after SES implantation. Moreover,
restenosis was significantly reduced from 36.3% with con-
ventional stents to 8.9% with SESs in the randomized
SIRolImUS-eluting Bx velocity balloon expandable stent trial
(SIRIUS)9 and from 42.3% to 5.9% in the E-SIRIUS trial,10
with diabetes, small vessel size, and long lesions being
identified as predictors of post-SES restenosis in the SIRIUS
trial.9 Nevertheless, these randomized studies have been
largely restricted to selected patients treated with single-
lesion elective stenting. The factors related to angiographic
restenosis after SES implantation in highly complex subsets
are currently unknown.
SES implantation was recently shown to effectively im-
prove the 1-year clinical outcomes in “real world” practice in
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patients enrolled in the Rapamycin-Eluting Stent Evaluated
At Rotterdam Cardiology Hospital (RESEARCH) study.11 In
the RESEARCH study, a parallel angiographic substudy was
conducted to evaluate the late angiographic findings of
complex patients treated with SESs. The present report aimed
to evaluate the value of clinical, angiographic, and procedural
factors in predicting the risk of binary restenosis in highly
complex patients treated with SES implantation in the RE-
SEARCH study.
Methods
Study Design and Patient Population
The design of the RESEARCH study has been reported previously.11
In brief, SES implantation (Cypher; Johnson & Johnson-Cordis unit,
Cordis Europa NV) was introduced as the default strategy for all
patients undergoing percutaneous coronary interventions in our
institution after April 2002. All procedures were performed accord-
ing to standard techniques, and the final interventional strategy was
left to the discretion of the operator, with the aim of achieving a final
residual stenosis 50% by online quantitative coronary angiography
in the presence of TIMI (Thrombolysis In Myocardial Infarction) 3
grade flow. The use of periprocedural glycoprotein IIb/IIIa inhibitors
and antithrombotic medications was left entirely to the discretion of
the attending team.
Patients receiving SESs were considered candidates for angio-
graphic reevaluation if they had at least 1 of the following charac-
teristics: (1) treatment of acute myocardial infarction, (2) treatment
of in-stent restenosis, (3) use of a very small SES (2.25-mm nominal
diameter), (4) treatment of left main coronary, (5) treatment of
chronic total occlusion (3 months), (6) total adjacent stented
segment longer than 36 mm, and (7) bifurcation stenting (SES
implanted in both the main vessel and the side branch). Patients with
the aforementioned characteristics who had not undergone repeat
intervention in the first month and had not presented any formal
medical contraindication for angiographic restudy were considered
eligible for angiographic follow-up at 6 to 8 months. Coronary
angiograms performed prematurely because of clinical indications
were used as the follow-up angiography if performed after 4 months
or if restenosis was detected. In other cases, a second angiogram was
obtained between 6 and 8 months. Importantly, although all patients
were approached for angiographic follow-up, patient refusal was not
considered as an exclusion criterion to be enrolled in the RE-
SEARCH study. Angiographic restudy was not requested for non-
residents of the Netherlands.
During the first 6 months of enrollment, a total of 362 consecutive
patients had at least 1 of the high-risk criteria listed above (57% of
all patients treated with SESs in the period). Of these, 2 patients
moved to another country, 10 had died within the first 6 months of
follow-up, 6 had repeat intervention before 30 days (surgical or
percutaneous), and 3 were considered to have a medical contraindi-
cation to the angiographic follow-up (1 patient with previous stroke
and disabling dementia, 1 with severe allergic contrast reaction at the
index procedure, and 1 with end-stage hepatic failure due to
autoimmune hepatitis). Of the remaining 341 patients, angiographic
reevaluation at 20434 days was obtained for 238 patients (70% of
eligible patients), who compose the present study population.
Quantitative Coronary Angiography
Quantitative coronary angiographic analysis was performed as de-
scribed previously with a validated computer-based edge-detection
system (CASS II, Pie Medical).12 Interpolated reference diameter,
minimal luminal diameter, and diameter stenosis were obtained at
baseline, after stenting, and at follow-up. In-stent restenosis was
defined by diameter stenosis 50% and was classified as in-stent if
inside the stent or in-segment if located within the stented segment
plus the 5-mm segments distal or proximal to the stent margins.9
Restenosis at an ostial location (within 3 mm of the vessel origin)
was classified as in-stent unless clearly located outside the limits of
the SES.13
Statistical Analysis
Continuous variables are presented as meanSD and were compared
with Student’s unpaired t test. Categorical variables are presented as
counts and percentages and compared with the Fisher exact test.
Demographic, clinical, procedural, and angiographic variables were
tested in univariate and multivariate logistic analyses for their value
in predicting binary restenosis. All variables shown in Tables 1 and
2 were considered in multivariate logistic regression analyses regard-
less of their univariate findings. The final model was built iteratively
and evaluated for lack of fit with the Hosmer-Lemeshow test. Global
predictive accuracy was assessed by means of the C-index (area
under the receiver operating characteristic curve). Finally, an internal
validation was performed with a bootstrap technique.14 The model
was repeatedly applied to 1000 replicated bootstrap samples, and the
C-index for each individual sample was calculated. The C-index
obtained from each bootstrap sample was then subtracted from the
initial C-index value of the original population. The average of the
differences was considered as a measure of optimism in the model
fit. Finally, a corrected C-index was calculated by subtracting the
average of the optimism estimates from the original C-index. The
bootstrap correction has been described as a nearly unbiased internal
validation, which penalizes for any model overfitting.14 Presented
95% CIs of all multivariate estimates were derived from the
bootstrap analysis.
Results
Among the 238 patients (441 lesions) included in this
analysis, 13 (6%) had left main coronary stenting, 35 (15%)
had at least 1 chronic total occlusion, 45 (19%) received
sirolimus stents to treat at least 1 restenotic lesion, 50 (21%)
TABLE 1. Clinical Characteristics of 238 Patients Treated With
SES Implantation
Characteristic No.
Male gender 73
Age, y 6012
Height, cm 1729
Weight, kg 8214
Hypercholesterolemia* 58
Hypertension 56
Diabetes mellitus 22
Insulin-dependent diabetes 6
Non–insulin-dependent diabetes 16
Previous myocardial infarction 32
Previous bypass surgery 11
Previous percutaneous intervention 28
Vessel disease
1-vessel disease 40
2-vessel disease 35
3-vessel disease 25
Clinical presentation
Stable angina 54
Unstable angina 21
Acute myocardial infarction 26
Periprocedural IIb/IIIa inhibitor 27
Values are percentages or meanSD.
*Total cholesterol 200 mg/dL or receiving lipid-lowering treatment.
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had bifurcation stenting, 62 (26%) were in the acute phase of
a myocardial infarction, 68 (28%) had at least one 2.25-mm
SES implanted, and 83 (35%) had very long stenting
(36 mm) in at least 1 vessel (Tables 1 and 2). On average,
1.410.81 stents were implanted per lesion, and 39% of
lesions had at least 2 stents that overlapped. Most lesions
were classified as American College of Cardiology/American
Heart Association type B2 or C (71%); 22% received bifur-
cation stenting (stent implanted in both the main vessel and
the side branch); 8% were chronic total occlusions (duration
3 months); and 3% were located in the left main coronary.
Mean vessel size was 2.500.61 mm (range 1.00 to
4.59 mm), and the average stented length was 26.020.3 mm
(range 8 to 117 mm).
At the follow-up angiogram, 7.9% of lesions had binary
in-segment restenosis. Of these, 6.3% were located inside the
stent (in-stent), 0.9% were located in the proximal edge, and
the remaining 0.7% occurred at the distal edge. Because of
the limited number of lesions with edge restenosis (7 obser-
vations), additional analyses were performed for all lesions
grouped as in-segment restenosis.
The Figure shows the univariate relationship between
demographic, angiographic, and procedural characteristics
and the incidence of post-SES restenosis, and significant
univariate parameters are shown in Table 3. In the multivar-
iate analysis, the following variables were identified as
independent predictors of restenosis: treatment of in-stent
restenosis, ostial location, presence of diabetes mellitus, total
TABLE 2. Procedural and Angiographic Characteristics of 441
Lesions Treated With SES Implantation
Characteristic No.
Treated vessel
Left main coronary 3
Left anterior descending 43
Left circumflex artery 22
Right coronary artery 30
Bypass graft 3
Lesion type
A 6
B1 23
B2 43
C 28
Chronic total occlusion 3 months 8
Moderate/severe angiographic calcification 7
Ostial location 22
Bifurcation treatment* 22
Treatment of in-stent restenosis 13
No. of stents implanted 1.410.81
Overlapping stents 39
Total stented length, mm 26.020.3
Stented length 36 mm 17
Use of 2.25-mm SES 18
Reference diameter, mm 2.500.61
Preprocedure minimal luminal diameter, mm 0.690.54
Preprocedure diameter stenosis, % 72.220.0
Lesion length, mm 16.111.8
Postprocedure minimal luminal diameter, mm 2.130.58
Postprocedure diameter stenosis, % 17.211.1
Follow-up minimal luminal diameter, mm 2.100.69
Follow-up diameter stenosis, % 22.819.9
Late loss, mm 0.040.49
Binary restenosis 7.9
In-stent 6.3
Proximal edge 0.9
Distal edge 0.7
Values are percentages or meanSD.
*SES implantation in both the main vessel and the side branch.
Univariate OR of binary angiographic in-segment restenosis
after SES restenosis according to demographic, clinical, proce-
dural, and angiographic characteristics. NIDDM indicates non–
insulin-dependent diabetes mellitus; IDDM, insulin-dependent
diabetes mellitus; pre, preprocedure; and post, postprocedure.
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stented length, reference diameter, and left anterior descend-
ing artery location (Table 4). The final multivariate model fit
the data well (Hosmer-Lemeshow test P0.94; 22.93;
df8) and had a good predictive accuracy (C-index 0.83),
which was virtually unchanged after the bootstrap correction
(corrected C-index 0.82). Actual restenosis rates for patients
with “high-risk” characteristics (derived from the multivari-
ate model) are shown in Table 5.
Discussion
The present study reported on the predictors of angiographic
restenosis after SES implantation in complex patients. Over-
all, our series included patients with smaller vessels and
longer lesions than in other trials conducted to date.8–10
Moreover, a considerable proportion of patients had previous
in-stent restenosis, bifurcation stenting, chronic total occlu-
sions, thrombus-containing lesions, and calcified vessels,
conditions that were formally excluded from previous trials.
Nevertheless, binary restenosis after SES implantation in
such a complex patient population was detected in only a
minority of cases (7.9% of lesions). The expected restenosis
rate for de novo lesions included in the present report would
range from 40.1% to 43.0% if treated with bare metal stents,
as calculated from prediction equations derived from previ-
ous meta-analysis with conventional stents.3,6
In the SIRIUS trial, small vessel size, long lesion length, and
diabetes were shown to significantly increase the incidence of
restenosis after SES.9 These characteristics were confirmed as
predictors of post-SES restenosis in the present study, which
additionally extended the list of independent parameters to
include ostial location and treatment of in-stent restenosis (as
negative factors) and left anterior descending artery location (as
a protective factor). Interestingly, most characteristics identified
as predictors of post-SES restenosis have long been recognized
as major predictors of restenosis after balloon angioplasty or
conventional bare stent implantation.1–7,15–17 It seems intuitive to
assume that the increased incidence of restenosis after SES
implantation in patients with these risk factors may reflect an
extreme background tendency to tissue reaction and neointimal
growth, which was not sufficiently inhibited by the antiprolif-
erative action of the drug.
Restenosis after SES has been shown to be associated with
incomplete lesion coverage in some cases, as detected by
intravascular ultrasound.13 In the present study, lesions in-
volving ostial sites had a higher risk of restenosis, which may
be related, at least in part, to technical difficulties in stent
positioning and vessel scaffolding at the ostium. We may
speculate that the presence of “traditional” risk factors for
restenosis may potentially act as a predisposing factor that
will lead to restenosis in case a subtle device-related or
procedure-related local failure is eventually superimposed.
Unfortunately, small gaps between stents and minor ruptures
in the metallic stent mesh or in the polymer integrity are not
detectable by conventional coronary angiography13 and could
not be evaluated in the present report.
The treatment of in-stent restenosis with SES was associated
with a more than 4-fold increase in the risk of restenosis after
adjustment for other independent variables. Although SES im-
plantation has been associated with low rates of repeat restenosis
after treatment of noncomplex in-stent restenosis,18,19 the effi-
cacy of this device for more complicated cases remains to be
established.20,21 Redilation of restenotic lesions (ie, exposure to
“double injury”) has been shown to trigger a peculiar local
vascular response, distinct from that observed after the first
dilation.22 Modifications in the reparative mechanisms, espe-
cially after endovascular brachytherapy,20 may decrease the
responsiveness of restenotic lesions to the antiproliferative drug.
TABLE 4. Clinical, Procedural, and Angiographic Multivariate
Predictors of In-Segment Restenosis After SES Restenosis*
OR 95% CI P
Treatment of in-stent restenosis 4.16 1.63–11.01 0.01
Ostial location 4.84 1.81–12.07 0.01
Diabetes mellitus 2.63 1.14–6.31 0.02
Total stented length (per 10-mm increase) 1.42 1.21–1.68 0.01
Reference diameter (per 1.0-mm increase) 0.46 0.24–0.87 0.03
Left anterior descending artery 0.30 0.10–0.69 0.01
*Intercept coefficient, 2.34.
TABLE 3. Clinical, Procedural, and Angiographic Univariate
Predictors of In-Segment Restenosis After SES Restenosis
OR 95% CI P
Bypass graft 4.61 1.39–15.33 0.01
Treatment of in-stent restenosis 3.66 1.68–7.96 0.01
Previous bypass surgery 3.24 1.42–7.41 0.01
Bifurcation stenting (side branch position) 2.77 1.15–6.33 0.02
Ostial location 2.66 1.30–5.46 0.01
Diabetes mellitus 2.54 1.24–5.21 0.01
No. of stents implanted 1.62 1.19–2.22 0.01
Postprocedure diameter stenosis
(per 10% increase)
1.55 1.14–2.10 0.01
Total stented length (per 10-mm increase) 1.30 1.14–1.48 0.01
Preprocedure minimal luminal diameter 0.46 0.22–0.95 0.04
Postprocedure minimal luminal diameter 0.39 0.20–0.76 0.01
Left anterior descending artery 0.37 0.16–0.82 0.02
Acute myocardial infarction 0    0.01
TABLE 5. Actual Rates of Post-SES In-Segment Restenosis
According to the Presence of High-Risk Characteristics*
In-Segment
Restenosis
Rate, %
Treatment of in-stent restenosis 19.6
Ostial location 14.7
Diabetes mellitus 14.3
Stented length 26 mm† 13.9
Reference diameter 2.17 mm‡ 10.3
Non-LAD location 10.8
LAD indicates left anterior descending artery.
*Presence of multivariate independent predictors.
†Higher tercile for stented length.
‡Lower tercile for reference diameter.
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Curiously, lesions located in the left anterior descending
artery had a decreased restenosis rate in the present series.
Whether this factor represents a true protective characteristic has
to be further investigated in future studies. Although post-SES
restenosis was not detected in any patient admitted with acute
myocardial infarction, this characteristic was not included in our
final multivariate model, which suggests that perhaps acute
myocardial infarction at admission per se was not an important
factor affecting restenosis in the present study population.
Post-SES restenosis in the present study was almost entirely
restricted to the segment inside the stent (80% of restenoses).
This finding represents a major difference from previous trials
with SES, in which restenosis more frequently occurred at the
stent edges.9,10 In the RESEARCH study, all operators were
strongly advised to actively cover the entire injured vessel area
and to avoid both residual dissection at stent borders and gaps
between stents. In addition, the stent placement strategy aimed to
cover the treated segment “from healthy tissue to healthy tissue,”
to avoid having the free borders of the stents terminate in grossly
diseased segments. However, it remains speculative whether
these procedural strategies might have had any impact in
reducing the incidence of restenosis at the stent edges.
Study Limitations
The present report may suffer from its relatively limited study
population, which was restricted to complex patients who
fulfilled predefined criteria to be included in this angio-
graphic substudy. Therefore, our results cannot be directly
extrapolated to the entire cohort of consecutive patients
treated in the RESEARCH study, and further analyses are
needed to fully assess the angiographic outcomes of subsets
not included in the present study. Ten patients with early
death could not be restudied at 6 months, and a higher rate of
angiographic follow-up (70% in this study) would be
desirable for a comprehensive evaluation. However, the
present study was designed to enroll all unselected patients
treated in our institution, and patient refusal for angiographic
follow-up did not preclude enrollment in the RESEARCH
study. Obviously, this real-life scenario differs substantially
from that of randomized trials and limits the compliance to
angiographic restudy.
Conclusions
Angiographic restenosis after SES implantation in complex
patients is an infrequent event (7.9% of lesions), occurring
mainly in association with local, lesion-based characteristics
and diabetes mellitus.
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